Neuromuscular

Here's what is coming soon to NeurologyLive.

The associate professor of neurology at Columbia University and medical consultant and care center director at the Muscular Dystrophy Association discussed the use of larger datasets to improve prognostication and clinical trials in ALS.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending May 7, 2021.

The associate professor of neurology at Columbia University and medical consultant and care center director, Muscular Dystrophy Association, discusses the impact that the Ice Bucket Challenge and ALS Awareness Month have had on the ALS treatment landscape.

Results showed that SRP-5051 30 mg/kg is likely to deliver greater than 10% dystrophin over time with monthly dosing in Duchenne muscular dystrophy.

Recent Foundation for Angelman Syndrome Therapeutics grants funded the hotline as well as work to develop cell line models for rarer genotypes of AS.

Lightheadness, loss of balance, vision changes, and abnormal eye movements led to the discovery of cancer in one specific patient.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending May 1, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 30, 2021.

Apic Bio plans to initiate a phase 1/2 clinical trial in late 2021 or early 2022 as a multi-center, 3-part study to evaluate APB-102 in patients with SOD1-ALS mutations.

Formerly known as BIIB067, the antisense oligonucleotide is expected to be available for rapidly progressing patients in mid-July 2021, and for the broader SOD1-ALS population in the fall.

Advances in MRI and MRS techniques and protocols enhance diagnosis of neuromuscular disorders and provide prognostic and intervention efficacy biomarkers.

Here's what is coming soon to NeurologyLive.

Three patients included in the study showed positive trends across both I-RODS and Jamar grip strength following treatment with lenalidomide.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 23, 2021.

In an AAN plenary talk, Mark H. Tuszynski, MD, PhD, detailed the work he and colleagues have done to push stem cell therapy from the lab to the clinic to improve care for spinal cord injury.

The 2021 AAN Meeting Hot Topics plenary focused on neurological facets of COVID-19, and featured insight from Anthony Fauci, MD, of NIAID, and Walter Koroshetz, MD, of NINDS, among others.

Here's what is coming soon to NeurologyLive.

Neurology News Network for the week ending April 17, 2021.

Take 5 minutes to catch up on NeurologyLive's highlights from the week ending April 16, 2021.

The ability to feed orally and swallow was maintained by an overwhelming number of patients treated with risdiplam at 24 months.

According to the study authors, future longitudinal studies assessing the evolution of cognitive and cortical excitability changes may provide a greater understanding of the importance of cortical circuits in ALS pathogenesis.

The 2021 AAN Annual Meeting will be held virtually from April 17-22. Follow along with coverage from NeurologyLive, including expert interviews and session recaps.

At 6 months, 62% of the 10 kHz spinal cord stimulation treatment group had observed improvement upon investigator-assessed neurological examination, compared to 3% of conventional medical management subjects.